Histogenics Corporation to Present at Upcoming Investor Conferences
August 24 2017 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, today announced that Company
Management will be presenting at three upcoming conferences in
September 2017.
- Baird 2017 Global Healthcare Conference – New York, NY
(September 6-7, 2017)Jonathan Lieber, Chief Financial
Officer of Histogenics, will be presenting a corporate overview on
Thursday, September 7 at 10:15 AM EDT. The conference will be
held at the InterContinental New York Barclay in New York
City. The presentation will be webcast live and may be
accessed by visiting the Investor Relations section of Histogenics’
website at www.histogenics.com. The webcast will be archived
and available on Histogenics’ website for 45 days following the
conferences.
- 19th Annual Rodman & Renshaw Global Investment
Conference – New York, NY (September 10-12, 2017)Jonathan
Lieber, Chief Financial Officer of Histogenics, will be presenting
a corporate overview on Monday, September 11 at 10:00 AM EDT.
The conference is sponsored by H.C. Wainwright & Co., LLC., and
will be held at the Lotte New York Palace Hotel in New York
City. The presentation will be webcast live and may be
accessed by visiting the Investor Relations section of Histogenics’
website at www.histogenics.com. The webcast will be archived
and available on Histogenics’ website for 45 days following the
conferences.
- Healthcare Capital & Connections Summit – Shanghai,
China (September 12-14, 2017)Adam Gridley, President and
Chief Executive Officer of Histogenics, will be presenting a
corporate overview on Wednesday, September 13 at 2:00 PM local
time. The conference is sponsored by Silicon Valley Bank,
AdvaMed Accel, Piper Jaffray and Vivo Capital and will be held at
the InterContinental Ruijin in Shanghai.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing novel tissue therapies that
may offer more rapid and durable recoveries for patients with pain
and loss of function due to musculoskeletal conditions.
Histogenics’ regenerative medicine platform combines
expertise in cell processing, scaffolding, tissue engineering and
bioadhesives to create tissue ex-vivo. Histogenics’ first
investigational product candidate, NeoCart is designed to treat
cartilage defects in the knee. The Company recently completed
enrollment of its NeoCart Phase 3 clinical trial and expects to
report top-line data in the third quarter of 2018. NeoCart is
designed to exhibit characteristics of articular, hyaline cartilage
prior to and upon implantation into the knee and therefore does not
rely on the body to make new cartilage. As a result, NeoCart
is the only product in development or on the market with a one-year
primary superiority endpoint as compared to the standard of
care. There are more than 500,000 or more knee cartilage
procedures in the United States each year, with many healthy active
adults avoiding treatment as they seek other alternatives.
Left untreated, even a small cartilage defect can expand in
size and progress to debilitating osteoarthritis, ultimately
necessitating a joint replacement procedure. Osteoarthritis
is more common in adults over the age of 50, but the condition and
precursors of the condition can be observed much earlier, and
cartilage damage is believed to be one of the leading contributors
of this disease. For more information, please visit
www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2024 to May 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From May 2023 to May 2024